Food insecurity, or lack of consistent access to enough food, is associated with low intakes of fruits and vegetables (FVs) and higher risk of chronic diseases and disproportionately affects populations with low income. Financial incentives for FVs are supported by the 2018 Farm Bill and United States (U.S.) Department of Agriculture's Gus Schumacher Nutrition Incentive Program (GusNIP) and aim to increase dietary quality and food security among households participating in the Supplemental Nutrition Assistance Program (SNAP) and with low income. Currently, there is no shared evaluation model for the hundreds of financial incentive projects across the U.S. Despite the fact that a majority of these projects are federally funded and united as a cohort of grantees through GusNIP, it is unclear which models and attributes have the greatest public health impact. We explore the evaluation of financial incentives in the U.S. to demonstrate the need for shared measurement in the future. We describe the process of the GusNIP NTAE, a federally supported initiative, to identify and develop shared measurement to be able to determine the potential impact of financial incentives in the U.S. This commentary discusses the rationale, considerations, and next steps for establishing shared evaluation measures for financial incentives for FVs, to accelerate our understanding of impact, and support evidence-based policymaking.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8621044 | PMC |
| http://dx.doi.org/10.3390/ijerph182212140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Use of Clinical Trial Characteristics to Estimate Costs of New Drug Development.
JAMA Netw Open
January 2025
RAND, Santa Monica, California.
Importance: Despite their importance to patients, health, and industry, the magnitude of investments in drug research and development (R&D) remain nebulous. New policies require more granular and transparent R&D cost estimates to better balance incentives for innovation and returns to developers.
Objective: To estimate per-drug R&D costs using a novel, reproduceable approach and to describe firm-level R&D costs per discrete unit of R&D activity (1 patient-month).
Achievements, priorities and strategies in pediatric nephrology in Europe: need for unifying approaches or acceptance of differences?
Front Pediatr
December 2024
Department of Pediatric Kidney, Liver, Metabolic and Neurological Diseases, Children's Hospital, Hannover Medical School, Hannover, Germany.
Background: There is a lack of information on the current healthcare systems for children with kidney diseases across Europe. The aim of this study was to explore the different national approaches to the organization and delivery of pediatric nephrology services within Europe.
Methods: In 2020, the European society for Paediatric Nephrology (ESPN) conducted a cross-sectional survey to identify the existing pediatric nephrology healthcare systems in 48 European countries covering a population of more than 200 million children.
Food Advertisement and Marketing Policies Aimed at Reducing Childhood Obesity: A Review of Existing Regulations in High-Income Countries.
Public Health Rev
December 2024
Institute of Health Economics and Management, Faculty of Economics and Business, University of Debrecen, Debrecen, Hajdu-Bihar, Hungary.
Objectives: To identify and evaluate the difference between voluntary and mandatory food marketing policies and regulations targeting childhood obesity and to study the role of media, the food industry, and private associations in implementing such policies.
Methods: A review of policies and legislation about unhealthy food marketing was conducted by searching and extracting relevant grey literature from the websites of international health agencies, food marketing pledge databases, GINA, and NOURISHING policy databases. Statutory laws and self-regulations of high-income countries were compared with each other and with the WHO recommendations.
Revising EU pharmaceutical legislation: will it foster drug repurposing?
Drug Discov Today
January 2025
Department of Clinical Epidemiology & Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, the Netherlands; Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands; REPO4EU consortium.
Repurposing off-patent drugs can be a potential source of low-cost treatments for patients with unmet medical needs. Here, we review the proposed new European Union (EU) pharmaceutical legislation in which two articles address drug repurposing. We find certain barriers hindering the adoption of these new incentives by academic and not-for-profit stakeholders, including lack of knowledge on regulatory aspects, pharmacovigilance, and restrictions in data protection.
View Article and Find Full Text PDFIndividual and community catalysts for Renewable Energy Communities (RECs) development.
Curr Opin Psychol
December 2024
Department of Human and Social Sciences, University of Salento, Italy. Electronic address:
This review examines factors catalyzing citizens' participation in Renewable Energy Communities (RECs), crucial for sustainable energy transitions. We analyze the interplay of individual and community elements promoting involvement in these collective projects. Individual drivers include pro-environmental values, economic incentives, desire for energy autonomy, and technical knowledge.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!